Recently, some studies have reported different fusion partners for TFE3, but owing to the rarity of such tumors, general understanding of tRCC molecular characteristics and underlying mechanisms has been limited. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.